Skip Navigation

European Heart Journal 2003 24(19):1707-1709; doi:10.1016/S0195-668X(03)00470-6
Copyright © 2003 by the European Society of Cardiology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Bates, E. R
Right arrow Articles by Lau, W. C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bates, E. R
Right arrow Articles by Lau, W. C
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

Drug–drug interactions involving antiplatelet agents

Eric R Batesa,*, Debabrata Mukherjeea and Wei C Laub

a Division of Cardiovascular Diseases, Department of Internal Medicine, University Hospital, University of Michigan, Ann Arbor, Michigan, USA
b Department of Anesthesiology, University Hospital, University of Michigan, Ann Arbor, Michigan, USA

* Correspondence to: Eric R. Bates, MD, Cardiology Division, University of Michigan Medical Center, B1 238 Taubman Center, 1500 E. Medical Center Dr. B1 238 TC, Ann Arbor, MI 48109, USA. Tel: +1 734-936-5840; Fax: +1 734-936-7026
E-mail address: ebates@umich.edu

Received 28 July 2003; accepted 31 July 2003

The first 10% of the full text of this article appears below.

See doi:10.1016/S1095-668X(03)00442-1 for the article to which this editorial refers

Antiplatelet therapy used to be a simple proposition. ‘An aspirin a day keeps the cardiologist away’ is a modified aphorism that has been true for more than two decades. This is now evidence-based, with the Antithrombotic Trialists’ Collaboration confirming that antiplatelet therapy in patients with atherosclerotic vascular disease reduces non-fatal myocardial infarction by one third, non-fatal stroke by one quarter, and vascular mortality by one sixth.1No other pharmacologic agent can challenge the risk-benefit or cost-benefit ratios of aspirin therapy. Aspirin is mandatory treatment for secondary prevention of cardiovascular events.

However, antiplatelet therapy has become more complex. In recent years, aspirin has been . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function — a flow cytometry study
Horst Neubauer, Bülent Günesdogan, Christoph Hanefeld, Martin Spiecker, and Andreas Mügge
EHJ 2003 24: 1744-1749. [Abstract] [Full Text]  



This article has been cited by other articles:


Home page
 Eur Heart JHome page
T. Geisler, C. Zurn, M. Paterok, K. Gohring-Frischholz, B. Bigalke, K. Stellos, P. Seizer, B. F. Kraemer, J. Dippon, A. E. May, et al.
Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy
Eur. Heart J., July 1, 2008; 29(13): 1635 - 1643.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
D Mukherjee, E Kline-Rogers, J Fang, K Munir, and K A Eagle
Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome
Heart, January 1, 2005; 91(1): 23 - 26.
[Abstract] [Full Text] [PDF]